Scalper1 News
SAN FRANCISCO — Celgene (CELG) was trading down Monday after the big biotech issued preliminary Q4 results and 2016 guidance that missed expectations, while also unveiling changes at the top of its management. At the annual JPMorgan Healthcare Conference in San Francisco, Celgene said that Q4 EPS totaled $1.18 a share, up 17% from the year-earlier quarter but missing analysts’ consensus by 9 cents, according to Thomson Reuters. Product sales Scalper1 News
Scalper1 News